Supplementary Table 2. Baseline characteristics and univariable analysis of 321 cases of APAP-ALF
INR, international normalized ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
*7-days: Values refer to therapies at any time during the 7-days of study No ICP monitoring (control)
group (N=252)
ICP monitoring (ICPM) group (N=69)
N Number (%) or median (IQR)
N Number (%) or median (IQR)
P value
Age 252 39.0 (29.0 - 49.0) 69 35.0 (26.0 - 39.0) 0.0007
Sex (female) 252 204 (90.0%) 69 57 (82.6%) 0.755
Race 252 69 0.117
White 218 (86.5%) 53 (76.8%)
African-American 22 (8.7%) 9 (13.0%)
Other 12 (4.8%) 7 (10.1%)
Etiology
Acetaminophen 252 252 (100.0%) 69 69 (100.0%)
Admission biochemistry
Hemoglobin (g/dl) 251 10.4 (9.3 - 11.9) 68 10.3 (9.2 - 11.8) 0.559 White Blood count (x109/L) 251 9.6 (6.4 - 14.3) 69 9.9 (6.4 - 14.3) 0.932 Platelet count (x109/L) 251 126.0 (76.0 - 181.0) 68 118.5 (77.5 - 194.0) 0.756
INR 249 3.0 (2.0 - 4.7) 67 2.5 (2.0 - 3.8) 0.228
AST (IU/L) 248 3642.0 (1189.5 - 7799.0) 69 2366.0 (1014.0 - 5846.0) 0.143 ALT (IU/L) 246 3295.0 (1427.0 - 5544.0) 69 3092.0 (1725.0 - 4986.0) 0.932 Bilirubin (mg/dl) 248 4.1 (2.4 - 6.2) 69 5.2 (4.2 - 7.5) 0.0004
pH 230 7.4 (7.3 - 7.5) 69 7.4 (7.4 - 7.5) 0.035
Ammonia (venous; μmol/L) 123 112.0 (77.0 - 170.0) 41 128 (83.0 - 180.0) 0.485
Creatinine (mg/dL) 252 2.0 (1.0 - 3.3) 68 2.1 (1.1 - 3.9) 0.393
Lactate (mmol/L) 173 5.3 (2.9 - 10.1) 51 5.0 (3.1 - 10.5) 0.738
Phosphate (mg/dL) 228 2.8 (2.0 - 4.0) 66 2.5 (1.7 - 3.3) 0.036
PO2/FiO2 ratio 207 3.6 (2.4 - 4.6) 63 3.6 (2.5 - 4.8) 0.949
MELD (admission) 245 32.0 (23.8 - 38.1) 66 32.0 (25.4 - 38.1) 0.670 Organ support (7-days)*
Mechanical ventilation 252 225 (89.3%) 69 68 (98.6%) 0.008
Vasopressors 252 97 (38.5%) 69 36 (52.2%) 0.041
Renal Replacement therapy 252 95 (37.7%) 69 36 (52.2%) 0.030
ICP therapies (7-days)
Mannitol 252 60 (23.8%) 69 41 (59.4%) <0.0001
Hypertonic saline 252 26 (10.3%) 68 11 (16.2%) 0.180
Barbiturates 252 19 (7.5%) 69 12 (17.4%) 0.014
Hypothermia 252 30 (11.9%) 68 22 (32.4%) <0.0001
Sedatives 252 205 (81.4%) 69 49 (71.0%) 0.061
Blood products (7-days)
Fresh Frozen Plasma 252 145 (57.5%) 69 55 (79.7%) 0.0008
Recombinant VIIA 252 5 (2.0%) 68 3 (4.4%) 0.374
Platelets 252 55 (21.8%) 69 30 (43.5%) 0.0003
Supplementary Table 3. Baseline characteristics and univariable analysis of 308 non- APAP-ALF patients
INR, international normalized ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; pO2, partial pressure of oxygen, FiO2, fraction of inspired oxygen.
*7-days: Values refer to therapies at any time during the 7-days of study No ICP monitoring (control)
group (N=237)
ICP monitoring (ICPM) group (N=71)
N Number (%) or median (IQR)
N Number (%) or median (IQR)
P value
Age 237 48.0 (34.0 - 59.0) 71 36.0 (26.0 - 50.0) <0.0001
Sex (female) 237 140 (59.1%) 71 44 (62.0%) 0.662
Race 237 71 0.464
White 157 (66.2%) 45 (63.4%)
African-American 52 (21.9%) 20 (28.2%)
Other 28 (11.8%) 6 (8.5%)
Etiology 236 71 0.027
Viral hepatitis 41 (17.4%) 18 (25.4%)
Drug Induced 42 (17.8%) 11 (15.5%)
Indeterminate 49 (20.8%) 23 (32.4%)
Other 104 (44.1%) 19 (26.8%)
Admission biochemistry
Hemoglobin (g/dl) 237 10.3 (9.2 - 12.1) 71 10.9 (9.1 - 13.0) 0.401 White Blood count (x109/L) 236 11.4 (8.1 - 16.3) 71 11.1 (8.4 - 15.2) 0.926 Platelet count (x109/L) 236 111.5 (67.0 - 177.5) 71 159.0 (93.0 - 220.0) 0.004
INR 232 2.7 (2.0 - 3.9) 66 2.8 (1.8 - 3.8) 0.674
AST (IU/L) 235 695.0 (280.0 - 2614.0) 70 958.5 (351.0 - 2423.0) 0.724 ALT (IU/L) 233 826.0 (295.0 - 2109.0) 70 1684.0 (460.0 - 2995.0) 0.097 Bilirubin (mg/dl) 235 17.0 (7.2 - 25.8) 70 16.2 (8.2 - 25.5) 0.967
pH 188 7.4 (7.4 - 7.5) 67 7.4 (7.4 - 7.5) 0.015
Ammonia (venous; μmol/L) 122 89.5 (57.0 - 159.0) 41 103.0 (85.0 - 170.0) 0.039
Creatinine (mg/dL) 237 2.0 (1.0 - 3.4) 71 1.6 (1.0 - 3.1) 0.210
Lactate (mmol/L) 135 4.3 (2.9 - 5.8) 42 4.8 (2.5 - 8.5) 0.893
Phosphate (mg/dL) 212 3.9 (1.9 - 4.3) 65 3.0 (2.2 - 4.5) 0.002
PO2/FiO2 ratio 156 2.9 (1.9 - 4.3) 59 3.1 (2.1 - 4.2) 0.678
MELD (admission) 230 34.4 (28.9 - 41.7) 65 33.8 (27.6 - 40.7) 0.310 Organ support (7-days)*
Mechanical ventilation 237 178 (75.1%) 71 69 (97.2%) <0.0001
Vasopressors 237 92 (38.8%) 71 41 (57.8%) 0.005
Renal Replacement therapy 237 91 (38.4%) 71 37 (52.1%) 0.040
ICP therapies (7-days)
Mannitol 237 40 (16.9%) 71 37 (52.1%) <0.0001
Hypertonic saline 237 10 (4.2%) 71 8 (11.3%) 0.026
Barbiturates 237 7 (3.0%) 71 23 (32.4%) <0.0001
Hypothermia 237 19 (8.0%) 71 11 (15.5%) 0.062
Sedatives 237 160 (67.5%) 71 46 (64.8%) 0.669
Blood products (7-days)
Fresh Frozen Plasma 237 152 (64.1%) 71 63 (88.7%) <0.0001
Recombinant VIIA 237 5 (2.1%) 71 0 (0.0%) 0.593
Platelets 237 65 (27.4%) 71 30 (42.3%) 0.018